Cardiomyopathy classification: Difference between revisions

Jump to navigation Jump to search
Line 119: Line 119:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{Sisakian H. Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J Cardiol. 2014;6(6):478-94.}}{{WH}}
{{WS}}
{{WS}}
[[Category:Best pages]]
[[Category:Best pages]]

Revision as of 05:07, 16 December 2018

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy classification

CDC on Cardiomyopathy classification

Cardiomyopathy classification in the news

Blogs on Cardiomyopathy classification

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cardiomyopathies refer to disorders of the heart muscle leading to its abnormal function and/or structure. It can generally be categorized into two groups, (based on World Health Organization guidelines) extrinsic cardiomyopathies and intrinsic cardiomyopathies [1]. Cardiomyopathy can be classified from a clinical standpoint, as to whether it is restrictive, dilated, or hypertrophic, and also by whether it is a primary cardiomyopathy, or a secondary cardiomyopathy as a result of another underlying process.

In 2013, the MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathies was proposed by the World Heart Federation[6]. This classification suggests a nosology that addresses five characteristics of cardiomyopathic disorders: morphofunctional state (M), organ involvement (O), genetic inheritance (G), etiologic annotation (E) and functional state (S) according to ACC/AHA A-D stage and New York Heart Association (NYHA) I-IV functional class.

Classification

Cardiomyopathies are myocardial diseases that are independent of:

Extrinsic Cardiomyopathies

These are cardiomyopathies where the primary pathology is outside the myocardium itself. Most cardiomyopathies are extrinsic, because by far the most common cause of a cardiomyopathy is ischemia. The World Health Organization calls these specific cardiomyopathies:[1]

Ischemic Cardiomyopathy

Ischemic cardiomyopathy is a weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease being the most common cause. Anemia and sleep apnea are other relatively common conditions that can contribute to ischemic myocardium and hyperthyroidism can cause a 'relative' ischemia secondary to high output heart failure. Individuals with ischemic cardiomyopathy typically have a history of myocardial infarction (heart attack), although longstanding ischemia can cause enough damage to the myocardium to precipitate a clinically significant cardiomyopathy even in the absence of myocardial infarction. In a typical presentation, the area of the heart affected by a myocardial infarction will initially become necrotic as it dies, and will then be replaced by scar tissue (fibrosis). This fibrotic tissue is akinetic; it is no longer muscle and cannot contribute to the heart's function as a pump. If the akinetic region of the heart is substantial enough, the affected side of the heart (i.e. the left or right side) will go into failure, and this failure is the functional result of an ischemic cardiomyopathy.

Cardiomyopathy Due to Systemic Diseases

Many diseases can result in cardiomyopathy. These include diseases like hemochromatosis, (an abnormal accumulation of iron in the liver and other organs), amyloidosis (an abnormal accumulation of the amyloid protein), diabetes, hyperthyroidism, lysosomal storage diseases and the muscular dystrophies.

Intrinsic Cardiomyopathies

An intrinsic cardiomyopathy is weakness in the muscle of the heart that is not due to an identifiable external cause. To make a diagnosis of an intrinsic cardiomyopathy, significant coronary artery disease should be ruled out (amongst other causes of extrinsic cardiomyopathy). The term intrinsic cardiomyopathy does not describe the specific etiology of weakened heart muscle. The intrinsic cardiomyopathies are a mixed-bag of disease states, each with their own causes.

Intrinsic cardiomyopathy has a number of causes including drug and alcohol toxicity, certain infections (including Hepatitis C), and various genetic and idiopathic (i.e., unknown) causes.

Intrinsic cardiomyopathies are generally classified into four types,[1][2] but additional types are also recognized:

  • Dilated cardiomyopathy (DCM), the most common form, and one of the leading indications for heart transplantation. In DCM the heart (especially the left ventricle) is enlarged and the pumping function is diminished. Approximately 40% of cases are familial, but the genetics are poorly understood compared with HCM. In some cases it manifests as peripartum cardiomyopathy, and in other cases it may be associated with alcoholism.
  • Hypertrophic cardiomyopathy (HCM or HOCM), a genetic disorder caused by various mutations in genes encoding sarcomeric proteins. In HCM the heart muscle is thickened, which can obstruct blood flow and prevent the heart from functioning properly.
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC) arises from an electrical disturbance of the heart in which heart muscle is replaced by fibrous scar tissue. The right ventricle is generally most affected.
  • Restrictive cardiomyopathy (RCM) is an uncommon cardiomyopathy. The walls of the ventricles are stiff, but may not be thickened, and resist the normal filling of the heart with blood. A rare form of restrictive cardiomyopathy is the obliterative cardiomyopathy, seen in the hypereosinophilic syndrome. In this type of cardiomyopathy, the myocardium in the apices of the left and right ventricles becomes thickened and fibrotic, causing a decrease in the volumes of the ventricles and a type of restrictive cardiomyopathy.
  • Noncompaction cardiomyopathy has been recognized as a separate type since the 1980s. The term refers to a cardiomyopathy where the left ventricle wall has failed to grow properly from birth and has a spongy appearance when viewed during an echocardiogram.

Alternate Detailed Classification Schemes

There are other more detailed classification schemes with a more complete differential diagnosis as shown below:

Clinical Classification

  • DILATED (D):
  • RESTRICTIVE (R):
    • Endomyocardial scarring or myocardial infiltration resulting in restriction to left and/or right ventricular filling. This entity is more common in the tropics.
  • HYPERTROPHIC (H):
    • Disproportionate left ventricular hypertrophy
      • Typically involving septum more than free wall
      • With or without an intraventricular systolic pressure gradient
        • Usually of a nondilated left ventricular cavity: the left ventricular cavity is either normal or reduced.

Primary Myocardial Involvement

Secondary Myocardial Involvement

References

  1. 1.0 1.1 1.2 Richardson, P.; et al. (1996). "Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies". Circulation. 93 (5): 841–2. PMID 8598070. (Full text)
  2. Cardiomyopathy Association. "About cardiomyopathy". September 28, 2006

Template:Sisakian H. Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J Cardiol. 2014;6(6):478-94.Template:WH Template:WS